Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to announce that the company’s common shares are now trading on the OTCQB Venture Market under the ticker "ZCTFF", alongside its existing listings on the TSX Venture Exchange and Frankfurt Stock Exchange. Ben-Haroosh emphasized that this milestone expands Zero Candida’s market presence, enhances strategic partnerships, and broadens the company’s investor base to support its AI-driven medical technology innovations. Zero Candida is pioneering a novel, non-drug treatment for Vulvo-Vaginal Candidiasis (VVC)—a condition affecting approximately 75% of women globally, with rising resistance to conventional antifungal treatments. The company is developing a tampon-like medical device that utilizes artificial intelligence and therapeutic blue light at a precise wavelength and intensity to eradicate Candida fungus. Early proof-of-concept (POC) studies have demonstrated an impressive 99.999% success rate in treating infections. With drug-resistant cases of recurrent VVC on the rise, Zero Candida’s innovative approach offers a groundbreaking alternative to existing treatments. Zero Candida has completed its preclinical trials with what Haroosh said was “100% safety,” and is preparing for clinical trials by the end of 2025, with market entry targeted after 2026 following FDA approval. #proactiveinvestors #zerocandida #tsxv #zct #WomensHealth #CandidaTreatment #MedicalDevice #Telemedicine #AIinHealthcare #NonDrugTherapy #OTCQB #HealthcareInnovation #FungalInfection